Median Technologies to participate in the 2023 ASCO Annual Meeting, June 2-6, 2023, McCormick Place, Chicago, IL, USA

Sophia-Antipolis, France

Press release – For immediate release – 5:45 pm CEST

Median Technologies to participate in the 2023 ASCO Annual Meeting, June 2-6, 2023, McCormick Place, Chicago, IL, USA

Median Technologies (ALMDT) announced today that the Company will be participating in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2 to 6, McCormick Place, Chicago, IL, USA. The Median team, with iCRO and iBiopsy® representatives as well as the Company clinical team will be pleased to welcome the ASCO participants at booth #2050, South Building, Hall A, McCormick place, from June 3 to 5 (exhibition dates), from 9:00 am to 5:00 pm.

Two Median Technologies’ abstracts have been selected for online publication:

Abstract #e20599: CT Based Radiomics Signature for Phenotyping Histopathological Subtype in Patients With Non-Small Cell Lung Cancer

The study in this abstract aimed to use a CT-based radiomics model to predict the histopathological subtype of non-small cell lung cancer (NSCLC) patients. The study included 678 patients, with 531 used for training and 147 for testing. The robust radiomics features extracted from the CT scans were used to train a support vector machine (SVM) classifier, which achieved an accuracy of 0.80 on the training set and 0.77 on the test set. The study showed that CT-based radiomics can accurately predict the histopathology subtype of NSCLC patients, offering a less invasive and more cost-effective alternative to traditional tissue analysis methods.

Abstract #e20515: Multicenter Evaluation of AI-Based CT Radiomics for EGFR Mutation Prediction in NSCLC

This abstract discusses using CT image-based radiomics model as a non-invasive solution to predict EGFR mutation status in NSCLC. The study collected CT images from multiple centers and open-source databases to investigate the performance of the model. The model achieved promising results with an AUC of 0.83 on cross-validation and an AUC of 0.76 on the test set. The authors conclude that AI-powered medical image analysis has the potential to serve as predictive biomarkers for guiding targeted therapies in the future.

The Median’s Imaging Lab team will be at booth #2050, to discuss abstract results. The team will also host two sessions on June 3rd and June 4th, at 4:15 pm CDT at booth, to highlight how Imaging Lab is shaping the future of clinical development with the latest in AI-powered imaging intelligence.

The ASCO Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology, the largest oncology society in the world. Each year, the ASCO conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO Annual Meeting:

Download 20230601_PR_ASCO2023_EN_final.pdf

About Median Technologies

Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China is listed  on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).


Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing and Financial Communications
+33 6 10 93 58 88

Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24